TY - JOUR
T1 - The promise of CAR T-cell therapy in aggressive B-cell lymphoma
AU - Nair, Ranjit
AU - Neelapu, Sattva S.
N1 - Funding Information:
This work is supported by generous philanthropic contributions to the University of Texas MD Anderson Moon Shots Program, Houston, Texas, USA and Grant from National Institutes of Health, USA ( P30 CA016672 ).
Publisher Copyright:
© 2018 Elsevier Ltd
PY - 2018/9
Y1 - 2018/9
N2 - Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the United States Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma after at least two lines of systemic therapy based on multicenter single-arm phase two clinical trials. Here, we will discuss the different components of the CAR construct and their mechanisms of action, the role of conditioning chemotherapy, the efficacy and toxicity observed with anti-CD19 CAR T-cell therapies in aggressive B-cell lymphomas, and emerging strategies to further improve the safety and efficacy of these highly promising approaches.
AB - Relapsed or refractory aggressive B-cell lymphoma has an extremely poor prognosis and efforts to develop novel therapies for these patients have failed for almost four decades until the advent of chimeric antigen receptor (CAR) T-cell therapy. Within the last one year, two anti-CD19 CAR T-cell therapy products, axicabtagene ciloleucel and tisagenlecleucel, were approved by the United States Food and Drug Administration for the treatment of relapsed or refractory large B-cell lymphoma after at least two lines of systemic therapy based on multicenter single-arm phase two clinical trials. Here, we will discuss the different components of the CAR construct and their mechanisms of action, the role of conditioning chemotherapy, the efficacy and toxicity observed with anti-CD19 CAR T-cell therapies in aggressive B-cell lymphomas, and emerging strategies to further improve the safety and efficacy of these highly promising approaches.
KW - Axicabtagene ciloleucel
KW - CAR T-cell
KW - Diffuse large B-cell lymphoma
KW - Tisagenlecleucel
UR - http://www.scopus.com/inward/record.url?scp=85051139252&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85051139252&partnerID=8YFLogxK
U2 - 10.1016/j.beha.2018.07.011
DO - 10.1016/j.beha.2018.07.011
M3 - Review article
C2 - 30213399
AN - SCOPUS:85051139252
SN - 1521-6926
VL - 31
SP - 293
EP - 298
JO - Best Practice and Research: Clinical Haematology
JF - Best Practice and Research: Clinical Haematology
IS - 3
ER -